JM 2947
Alternative Names: AJH-2947; JM-2947Latest Information Update: 15 Dec 2023
At a glance
- Originator JMackem
- Class Analgesics; Small molecules
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
Most Recent Events
- 27 Nov 2023 Phase-I clinical trials in Diabetic neuropathies (In volunteers) in South Korea (PO) (NCT06155487)
- 27 Nov 2023 Phase-I clinical trials in Neuropathic pain (In volunteers) in South Korea (PO) (NCT06155487)
- 27 Nov 2023 Phase-I clinical trials in Postherpetic neuralgia (In volunteers) in South Korea (PO) (NCT06155487)